Dr. Asif Shaikh is a physician researcher with over twelve years standing interest in the care of respiratory diseases, especially COPD, Asthma and IPF (Idiopathic Pulmonary Fibrosis). He recently co-authored three abstracts which received GOLD RIBBON Awards at the American Managed Care Pharmacy Congress (AMCP, Dallas 2017). The abstracts were, "Assessment In a Real-World Setting of the Effect of Inhaled Steroid-Based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease Exacerbations: AIRWISE study design", "Healthcare resource utilization, costs, and exacerbation rates in patients with COPD stratified by GOLD airflow limitation classification in a US commercially insured population" and "Spirometry Evaluation to Assess Performance of a Claims-Based Predictive Model that Identifies Patients Likely to Have Undiagnosed Chronic Obstructive Pulmonary Disease". Additionally, another abstract, "Real-world treatment patterns among newly diagnosed COPD patients according to GOLD airflow limitation severity classification in a US commercially insured / Medicare Advantage population" was accepted for "Oral Presentation" at the American College of Chest Physicians Congress (ACCP/CHEST), Toronto, Canada 2017. Dr. Shaikh is the medical lead for "AIRWISE" and MURDOCK COPD" study. AIRWISE is the world's largest ever pragmatic clinical trial, designed to test a medication's effectiveness in routine clinical practice settings (3200 patients). MURDOCK COPD Study is a prospective observational study aimed at achieving a better understanding of COPD progression in 850 patients. In the past few years, he has authored over 10 abstracts/posters. One of his publication is on a prospective cluster-randomized study published in the International Journal of Chronic Obstructive Pulmonary Disease, Volume 2012:7 Pages 437-445. He is working on four additional manuscripts to be published soon. Dr. Shaikh engages with Health Insurance Industry's Clinical Research wing, academia and is currently focused on generating real world evidence data for COPD pharmacotherapy. He works as Senior Director in the Department of Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals.

Focus Area/Interests

• Respiratory diseases care
• Chronic Obstructive Pulmonary Disease (COPD)
• Idiopathic Pulmonary Fibrosis (IPF)
• Clinical Trials
• Pharmacotherapy
• Health Insurance Industry Research

Current Position

• Senior Director in the Department of Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals

Career Experience

• Co-authored award-winning abstracts presented at major medical congresses
• Medical lead for significant clinical trials and observational studies
• Published research in peer-reviewed journals
• Preparing multiple manuscripts for publication
• Over twelve years of experience in physician research with a focus on respiratory diseases